What is HC Wainwright’s Forecast for OLMA FY2024 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright increased their FY2024 earnings per share estimates for Olema Pharmaceuticals in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($2.23) per share for the year, up from their previous estimate of ($2.34). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.35) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2024 earnings at ($0.53) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.84) EPS and FY2028 earnings at ($3.28) EPS.

Olema Pharmaceuticals Trading Up 0.4 %

NASDAQ:OLMA opened at $6.75 on Friday. The stock has a market capitalization of $386.76 million, a PE ratio of -3.08 and a beta of 1.92. The firm has a fifty day simple moving average of $10.70 and a 200 day simple moving average of $11.88. Olema Pharmaceuticals has a 1-year low of $6.24 and a 1-year high of $16.77.

Institutional Investors Weigh In On Olema Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Conway Capital Management Inc. bought a new stake in Olema Pharmaceuticals in the 3rd quarter worth about $119,000. China Universal Asset Management Co. Ltd. lifted its stake in Olema Pharmaceuticals by 67.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after purchasing an additional 4,442 shares during the last quarter. Portland Investment Counsel Inc. purchased a new stake in Olema Pharmaceuticals in the third quarter worth $143,000. SG Americas Securities LLC bought a new position in Olema Pharmaceuticals during the third quarter worth about $156,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Olema Pharmaceuticals in the second quarter valued at approximately $145,000. Institutional investors own 91.78% of the company’s stock.

Insider Transactions at Olema Pharmaceuticals

In related news, CEO Sean Bohen sold 52,328 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $490,313.36. Following the transaction, the chief executive officer now owns 298,836 shares in the company, valued at $2,800,093.32. The trade was a 14.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David C. Myles sold 12,452 shares of Olema Pharmaceuticals stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.38, for a total transaction of $116,799.76. Following the completion of the sale, the insider now owns 611,947 shares of the company’s stock, valued at $5,740,062.86. This represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 73,036 shares of company stock valued at $684,472. 19.40% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.